ChromaDex announces results from phase II study of NR supplementation
PremiumThe FlyChromaDex announces results from phase II study of NR supplementation
1M ago
ChromaDex receives orphan drug designation for Ataxia Telangiectasia cadidate
PremiumThe Fly
ChromaDex receives orphan drug designation for Ataxia Telangiectasia cadidate
2M ago
ChromaDex price target raised to $6.70 from $6.40 at Ladenburg
PremiumThe Fly
ChromaDex price target raised to $6.70 from $6.40 at Ladenburg
3M ago
Biotech Alert: Searches spiking for these stocks today
PremiumThe FlyBiotech Alert: Searches spiking for these stocks today
4M ago
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
4M ago
ChromaDex price target raised to $6 from $5 at H.C. Wainwright
PremiumThe Fly
ChromaDex price target raised to $6 from $5 at H.C. Wainwright
5M ago
ChromaDex, Neurohacker Collective partner for Qualia NAD+
PremiumThe FlyChromaDex, Neurohacker Collective partner for Qualia NAD+
8M ago
ChromaDex shares results of high dose Niagen and mild improvements in PD
PremiumThe Fly
ChromaDex shares results of high dose Niagen and mild improvements in PD
8M ago
ChromaDex: Study shows Niagen supplementation increases whole blood NAD+ levels
PremiumThe Fly
ChromaDex: Study shows Niagen supplementation increases whole blood NAD+ levels
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100